Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,765 INR | -0.04% | +3.86% | +8.74% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- With an expected P/E ratio at 45.81 and 39.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.74% | 3.29B | - | ||
+38.59% | 727B | C+ | ||
-7.89% | 347B | C+ | ||
+15.66% | 319B | B- | ||
+0.24% | 274B | C+ | ||
+13.47% | 238B | B+ | ||
+7.35% | 204B | B- | ||
-6.42% | 203B | A+ | ||
+4.23% | 161B | C+ | ||
-1.70% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JBCHEPHARM Stock
- JBCHEPHARM Stock
- Ratings J. B. Chemicals & Pharmaceuticals Limited